Skip to search formSkip to main contentSkip to account menu

BMS-207147

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Ravuconazole (BMS-207147, ER-30346), an oral triazole, was evaluated in an immunosuppressed temporarily neutropenic guinea pig… 
Review
2002
Review
2002
Systemic antifungal chemotherapy is enjoying its most dynamic era. More antifungal agents are under development than ever before… 
Highly Cited
2001
Highly Cited
2001
ABSTRACT The most important role of susceptibility testing is to identify potentially resistant isolates for the agent being… 
Highly Cited
2000
Highly Cited
2000
ABSTRACT The in vitro activities of the new triazole, ravuconazole (BMS-207147), were compared to those of fluconazole and… 
Highly Cited
2000
Highly Cited
2000
ABSTRACT The in vitro activity of BMS-207147 against 80 clinical isolates ofAspergillus was compared with that of itraconazole… 
1999
1999
ABSTRACT We compared the in vitro activity of BMS-207147, an investigational triazole, with those of itraconazole and fluconazole… 
Highly Cited
1998
Highly Cited
1998
ABSTRACT The antifungal activity of BMS-207147 (also known as ER-30346) was compared to those of itraconazole and fluconazole… 
Highly Cited
1998
Highly Cited
1998
ABSTRACT BMS-207147, Sch 56592, and voriconazole are three new investigational triazoles with broad-spectrum antifungal activity…